Ana Ayala

1.5k total citations
16 papers, 474 citations indexed

About

Ana Ayala is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Ana Ayala has authored 16 papers receiving a total of 474 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 8 papers in Pathology and Forensic Medicine and 5 papers in Oncology. Recurrent topics in Ana Ayala's work include Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (8 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Ana Ayala is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (8 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Ana Ayala collaborates with scholars based in United States, Spain and Australia. Ana Ayala's co-authors include Peter McLaughlin, Fredrick B. Hagemeister, Jorge Romaguera, Maria Alma Rodriguez, Fernando Cabanillas, Mark A. Hess, Barbara Pro, Anas Younes, Apostolia M. Tsimberidou and Ming-Sheng Lee and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Ana Ayala

16 papers receiving 466 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ana Ayala United States	9	381	270	196	72	64	16	474
Sabine Neser Germany	4	386 1.0×	282 1.0×	200 1.0×	53 0.7×	51 0.8×	6	435
Ursula Haak Germany	2	413 1.1×	280 1.0×	229 1.2×	54 0.8×	51 0.8×	4	448
C. Foussard France	12	375 1.0×	263 1.0×	236 1.2×	54 0.8×	63 1.0×	25	517
Emmanuelle Nicolas‐Virelizier France	13	424 1.1×	285 1.1×	195 1.0×	29 0.4×	75 1.2×	58	585
M. Bast United States	8	558 1.5×	347 1.3×	200 1.0×	52 0.7×	65 1.0×	10	609
Santiago Mercadal Spain	12	567 1.5×	403 1.5×	235 1.2×	45 0.6×	158 2.5×	56	710
Doreen M. Hallman United States	6	583 1.5×	517 1.9×	308 1.6×	60 0.8×	46 0.7×	8	688
Karin E. Summers United Kingdom	9	404 1.1×	280 1.0×	251 1.3×	23 0.3×	79 1.2×	11	608
K. Adams United Kingdom	6	326 0.9×	261 1.0×	135 0.7×	21 0.3×	80 1.3×	8	520
Antonio Léon Spain	8	402 1.1×	317 1.2×	127 0.6×	28 0.4×	187 2.9×	8	615

Countries citing papers authored by Ana Ayala

Since Specialization

Citations

This map shows the geographic impact of Ana Ayala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Ayala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Ayala more than expected).

Fields of papers citing papers by Ana Ayala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana Ayala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Ayala. The network helps show where Ana Ayala may publish in the future.

Co-authorship network of co-authors of Ana Ayala

This figure shows the co-authorship network connecting the top 25 collaborators of Ana Ayala. A scholar is included among the top collaborators of Ana Ayala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Ayala. Ana Ayala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Thompson, Philip A., Michael J. Keating, Alessandra Ferrajoli, et al.. (2022). Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year. Blood. 140(Supplement 1). 238–240. 1 indexed citations

Gorospe, Luis, Ana Ayala, Javier Martínez‐Sanz, et al.. (2021). Implementation of a lung cancer screening initiative in HIV-infected subjects. PLoS ONE. 16(12). e0260069–e0260069. 5 indexed citations

Jain, Nitin, Alessandra Ferrajoli, Philip A. Thompson, et al.. (2021). Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation. Blood. 138(Supplement 1). 1550–1550. 16 indexed citations

Thompson, Philip A., Yan Wang, Michael J. Keating, et al.. (2021). Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease. Blood. 138(Supplement 1). 3723–3723. 2 indexed citations

Thompson, Philip A., Alessandra Ferrajoli, Nitin Jain, et al.. (2020). The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL. Blood. 136(Supplement 1). 28–29. 7 indexed citations

Nastoupil, Loretta J., Peter McLaughlin, Lei Feng, et al.. (2017). High ten‐year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R‐FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. British Journal of Haematology. 177(2). 263–270. 12 indexed citations

Ferrajoli, Alessandra, Lorenzo Falchi, Susan O’Brien, et al.. (2012). Combination of Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial. Blood. 120(21). 720–720. 8 indexed citations

Ferrajoli, Alessandra, Susan O’Brien, William G. Wierda, et al.. (2011). Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial. Blood. 118(21). 1788–1788. 4 indexed citations

Ferrajoli, Alessandra, Stefan Faderl, Susan O’Brien, et al.. (2008). Experience with Fludarabine, Cyclophosphamide, Rituximab (FCR) Plus GM-CSF in Frontline Therapy for Chronic Lymphocytic Leukemia (CLL). Blood. 112(11). 3173–3173. 3 indexed citations

10.

McLaughlin, Peter, Sattva S. Neelapu, Michelle A. Fanale, et al.. (2008). R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma. Blood. 112(11). 3056–3056. 14 indexed citations

11.

Liu, Qi, Luis Fayad, Fernando Cabanillas, et al.. (2006). Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center. Journal of Clinical Oncology. 24(10). 1582–1589. 148 indexed citations

12.

Tsimberidou, Apostolia M., Anas Younes, Jorge Romaguera, et al.. (2005). Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer. 104(2). 345–353. 22 indexed citations

13.

McLaughlin, Peter, Elihu H. Estey, Armand B. Glassman, et al.. (2005). Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood. 105(12). 4573–4575. 59 indexed citations

14.

Seymour, John F., Barbara Pro, Lillian M. Fuller, et al.. (2003). Long-Term Follow-Up of a Prospective Study of Combined Modality Therapy for Stage I–II Indolent Non-Hodgkin’s Lymphoma. Journal of Clinical Oncology. 21(11). 2115–2122. 96 indexed citations

15.

Tsimberidou, Apostolia M., Peter McLaughlin, Anas Younes, et al.. (2002). Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood. 100(13). 4351–4357. 47 indexed citations

16.

Luna-Moré, Sebastián, et al.. (1997). Neutral and Acid Mucins and Eosinophil and Argyrophil Crystalloids in Carcinoma and Atypical Adenomatous Hyperplasia of the Prostate. Pathology - Research and Practice. 193(4). 291–298. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact